Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)
Sponsor: Genexine, Inc.
A observational or N/A phase clinical study on Cervical Intraepithelial Neoplasia 3, this trial is ongoing. The trial is conducted by Genexine, Inc. and has accumulated 12 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Aug 2019 — Nov 2020 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genexine, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .